Physician profile
Grace Hyun
NPI 1699829630
$851,751.52
in general payments reported to CMS, 2019-2025
18 companies · $455 in 2025
The $455 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $739 · 2021: $510 · 2022: $734K · 2023: $61K · 2024: $55K · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Food and Beverage: $3,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,558.00 |
| Food and Beverage | $3,231.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veru INC. | $845,509.64 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $1,541.02 | 2020-2025 | Oxlumo, Givlaari |
| Palette Life Sciences, INC. | $1,133.31 | 2020-2023 | |
| Biomarin Pharmaceutical INC. | $900.00 | 2023 | |
| Boston Scientific Corporation | $848.33 | 2022-2024 | Lithovue, Ams 700 |
| Teleflex LLC | $563.05 | 2024-2025 | Deflux, Deflux Metal Needle |
| Abbvie INC. | $367.76 | 2022-2024 | |
| Travere Therapeutics, INC. | $233.68 | 2019-2025 | |
| Urogen Pharma, INC. | $226.07 | 2023-2025 | Jelmyto |
| Novo Nordisk INC | $121.78 | 2024 | Rivfloza |
| Allergan, INC. | $71.89 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.57 | 2024-2025 | Xifaxan |
| Astellas Pharma Global Development | $55.13 | 2021 | |
| Merck Sharp & Dohme LLC | $32.93 | 2024 | |
| Antares Pharma, INC. | $26.99 | 2025 | Xyosted |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $21.97 | 2025 | |
| Sumitomo Pharma America, INC. | $21.09 | 2025 | Gemtesa |
| Astellas Pharma US INC | $13.31 | 2023 | Myrbetriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Hyun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.